These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21122673)

  • 1. NLA Symposium screening and treatment of familial hypercholesterolemia: how can we do better? Opening and introductions.
    McGowan M
    J Clin Lipidol; 2010; 4(5):335-7. PubMed ID: 21122673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
    Benítez S; Ordóñez-Llanos J; Franco M; Marín C; Paz E; López-Miranda J; Otal C; Pérez-Jiménez F; Sánchez-Quesada JL
    Am J Cardiol; 2004 Feb; 93(4):414-20. PubMed ID: 14969613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric implications of heterozygous familial hypercholesterolemia. Screening and dietary treatment.
    Kwiterovich PO
    Arteriosclerosis; 1989; 9(1 Suppl):I111-20. PubMed ID: 2563219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial hypercholesterolaemia: optimum treatment strategies.
    Ballantyne CM
    Int J Clin Pract Suppl; 2002 Jul; (130):22-6. PubMed ID: 12296605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
    Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
    Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial defective apolipoprotein B-100.
    Hansen PS
    Dan Med Bull; 1998 Sep; 45(4):370-82. PubMed ID: 9777289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of coronary heart disease in familial hypercholesterolemia].
    Miserez AR; Keller U
    Ther Umsch; 1994 Oct; 51(10):671-6. PubMed ID: 7839323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
    Vogt A; Parhofer KG
    Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population.
    Assouline L; Levy E; Feoli-Fonseca JC; Godbout C; Lambert M
    Pediatrics; 1995 Aug; 96(2 Pt 1):239-46. PubMed ID: 7630677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.
    Fouchier SW; Defesche JC; Kastelein JJ; Sijbrands EJ
    Semin Vasc Med; 2004 Aug; 4(3):259-64. PubMed ID: 15630635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mipomersen and its use in familial hypercholesterolemia.
    Parham JS; Goldberg AC
    Expert Opin Pharmacother; 2019 Feb; 20(2):127-131. PubMed ID: 30526168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Chinese homozygote of familial hypercholesterolemia: identification of a novel C263R mutation in the LDL receptor gene.
    Wang D; Wu B; Li Y; Heng W; Zhong H; Mu Y; Wang J
    J Hum Genet; 2001; 46(3):152-4. PubMed ID: 11310584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.